Last Price$177.02.3%
Market Cap$19.6B
6.7%
Peers median - 0.4%
9.2%
Peers median - 18.7%
102.2%
Peers median - 28.2%
8.8%
Peers median - 11.7%
Competing with DGX
Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name | Market Cap | Quality rating | Intrinsic value | 1Y Return | Revenue | Free Cash Flow | Revenue growth | FCF margin | Gross margin | ROIC | Total Debt to Equity |
$19.6B | 6.0 | $369.8 109.0% undervalued | 44.2% | $9,872.0M | $909.0M | 6.7% | 9.2% | 32.4% | 8.8% | 102.2% | |
$201.0B | 6.5 | $602.4 15.0% undervalued | (9.7%) | $42.9B | $7,267.0M | 0.1% | 16.9% | 41.5% | 8.3% | 63.1% | |
$151.3B | 6.1 | $167.0 18.8% overvalued | (19.4%) | $23.9B | $5,296.0M | (0.1%) | 22.2% | 59.5% | 5.9% | 32.3% | |
$36.5B | 7.4 | $103.7 17.9% overvalued | (11.0%) | $6,533.0M | $1,409.0M | (3.0%) | 21.6% | 65.9% | 14.7% | 55.8% | |
$36.1B | 7.2 | $219.3 49.8% overvalued | (23.5%) | $3,897.5M | $798.1M | 6.5% | 20.5% | 61.1% | 49.4% | 6.3% | |
$33.7B | 6.1 | $301.3 63.0% undervalued | (26.5%) | $15.4B | $2,114.0M | 2.5% | 13.7% | 31.4% | 8.8% | 21.7% | |
$27.1B | 7.0 | $869.6 31.5% overvalued | (1.4%) | $3,872.4M | $864.4M | 2.2% | 22.3% | 59.1% | 49.8% | (1,587.1%) | |
$22.2B | 6.5 | $236.1 36.5% overvalued | 7.2% | $2,958.4M | $619.6M | 0.1% | 20.9% | 58.2% | 19.4% | 0.0% | |
$21.2B | 6.1 | $621.0 144.4% undervalued | 17.1% | $13.0B | $1,095.9M | 0.8% | 8.4% | 26.9% | 6.0% | 24.1% | |
$18.5B | 6.0 | $70.9 50.4% overvalued | 58.6% | $1,532.0M | ($33.2M) | 54.9% | (2.2%) | 57.7% | (44.9%) | 54.2% | |
$13.9B | 6.2 | $147.2 74.8% undervalued | (37.1%) | $4,372.0M | $696.0M | (2.9%) | 15.9% | 65.4% | 34.6% | 93.8% |
Compare DGX Valuation Multiples with Peers
LTM
NTM
1Y Forward
2Y Forward
EV/Revenue
General
Valuation Multiple
Financial metrics
Company name
EV/Revenue
Revenue growth
EBITDA margin
Net Income margin
Quest Diagnostics IncorporatedDGX
2.6x
(6.4%)
(6.5%)
9.2%
Median Peer Set
6.4x
(0.3%)
(2.7%)
15.2%
Agilent Technologies, Inc.A
5.9x
(4.7%)
5.0%
19.8%
Danaher CorporationDHR
6.9x
(0.1%)
(17.9%)
16.3%
IDEXX Laboratories, Inc.IDXX
9.2x
8.7%
25.2%
23.1%
Illumina, Inc.ILMN
3.5x
(2.9%)
4.6%
(28.0%)
IQVIA Holdings Inc.IQV
2.2x
2.8%
2.4%
8.9%
Laboratory Corporation of America HoldingsLH
N/A
(18.3%)
(65.8%)
3.4%
Mettler-Toledo International Inc.MTD
7.5x
2.2%
12.7%
22.3%
Natera, Inc.NTRA
11.8x
32.0%
(32.1%)
(40.2%)
Thermo Fisher Scientific Inc.TMO
5.3x
(4.6%)
(12.4%)
14.0%
Waters CorporationWAT
7.4x
(0.5%)
(7.9%)
21.7%
Compare DGX Valuation Multiples Dynamics with Peers
Crunching data... Almost there!
FAQ
1. How does Quest Diagnostics Incorporated (DGX) revenue growth compare to peers and the industry?
Quest Diagnostics Incorporated (DGX) revenue growth is 6.7%, compared to the peers' median of 0.4%.
2. How does Quest Diagnostics Incorporated (DGX) Free Cash Flow (FCF) margin compare to peers and the industry?
Quest Diagnostics Incorporated (DGX) FCF margin is 9.2%, compared to the peers' median of 18.7%.
3. How does Quest Diagnostics Incorporated (DGX) Total Debt to Equity ratio compare to peers and the industry?
Quest Diagnostics Incorporated (DGX) Total Debt to Equity ratio is 102.2%, compared to the peers' median of 28.2%.
4. How does Quest Diagnostics Incorporated (DGX) ROIC (Return on Invested Capital) compare to peers and the industry?
Quest Diagnostics Incorporated (DGX) ROIC is 8.8%, compared to the peers' median of 11.7%.